secwatch.observer — SEC 8-K summary
======================================

Issuer:     uniQure N.V. (QURE)
CIK:        0001590560
Form:       8-K
Filed at:   2024-09-23T23:59:59+00:00
Accession:  0001558370-24-012941
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

uniQure receives FDA Orphan Drug Designation for AMT-191 gene therapy for Fabry disease
--------------------------------------------------------------------------------

- FDA granted Orphan Drug Designation to AMT-191 for Fabry disease on Sep 23, 2024.
- AMT-191 is a one-time IV AAV5-based gene therapy delivering a GLA transgene.
- First patient dosed in Aug 2024 in a U.S. multi-center open-label Phase I/IIa trial.
- Designation provides tax credits, fee waivers, and 7-year US market exclusivity if approved.
- Initial Phase I/IIa clinical data expected in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590560/000155837024012941/0001558370-24-012941-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590560/000155837024012941/qure-20240923x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-012941

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer